Safety of ACE-I and ARB medications in COVID-19: A retrospective cohort study of inpatients and outpatients in California.
Samuel J S RubinSamuel R FalksonNicholas R DegnerCatherine A BlishPublished in: Journal of clinical and translational science (2021)
These findings suggest that the use of ACE-I and ARB is not associated with adverse outcomes and may be associated with improved outcomes in COVID-19, which is immediately relevant to care of the many patients on these medications.
Keyphrases
- coronavirus disease
- sars cov
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- healthcare
- ejection fraction
- angiotensin ii
- angiotensin converting enzyme
- palliative care
- prognostic factors
- peritoneal dialysis
- quality improvement
- type diabetes
- adipose tissue
- respiratory syndrome coronavirus
- health insurance